Polypeptide With Localisation/Targeting Motif TRIZ Cases

Catalytically inactive Cas9 delivers effector domains to the MeCP2 locus, increasing transcription without introducing genetic disruptions.

A chimeric receptor fuses a PD-1 extracellular domain with a 4-1BB intracellular signaling module to drive T cell proliferation and IFN-gamma secretion.

Recombinant bacterial effector proteins autonomously penetrate eukaryotic cells to modulate immune responses.

Segmenting the receptor from the targeting module controls immune activation and prevents tumor escape variants.

Segmented Type I CRISPR-Cas effector complexes optimize subunit interactions to resolve the trade-off between genome editing efficiency and fidelity.

Chimeric antigen receptors on natural killer cells bind the coronavirus spike protein to enable targeted cell killing.

Fusing advanced macromolecule transduction domains with Parkin recombinant proteins overcomes blood-brain barrier penetration limits.

Anti-glyco-MUC4 antibodies recognize aberrant O-linked glycans on tumor cells, resolving the trade-off between therapeutic efficacy and healthy tissue damage.

Peptide probes replace post-mortem analysis with non-invasive imaging, resolving the trade-off between diagnostic accuracy and treatment monitoring speed.

Merging anti-CD19 and anti-CD20 sequences into one transcript enables T cells to target cancer cells that downregulate specific antigens.

Grl/Ag fusion polypeptides self-assemble into sub-micron granular particles that mimic virus-like structures.

Engineered T cell receptors bridge immune recognition gaps to eliminate integrated HIV provirus in latently infected cells.

A chimeric antigen receptor heterodimer links MHC domains to TCR intracellular regions on mammalian cells.

A PTH-Fc fusion protein extends serum half-life through FcRn-mediated recycling.

ARRDC1-mediated microvesicles deliver Cas9 proteins while avoiding viral immune responses and improving targeting specificity.

Variable surface protein carriers protect bioactive peptides from enzymatic and pH-induced degradation in the stomach, enabling effective systemic absorption.

High-affinity BCMA-specific chimeric antigen receptors resolve off-tumor toxicity by leveraging selective antigen expression on malignant cells.

Anti-CD40 antibody fused with HIV antigen targets dendritic cells via CD40 receptors to deliver immunogens directly.

Purifying native BAD-1 protein via nickel-chelating resin eliminates instability from recombinant tags, reducing false positives in blastomycosis diagnostics.

Fusing antigens to HIV gag polypeptides increases surface density, resolving poor incorporation efficiency and enhancing neutralizing antibody elicitation.

Engineered alpha-amylases retain at least 75% activity after pepsin exposure, reducing enzyme dosage and improving feed efficacy.

The Endo5 pentapeptide crosses cell membranes via passive diffusion, delivering cargo moieties while inhibiting vascular permeability and nitric oxide release.

A bispecific chimeric antigen receptor combines anti-CD19 and anti-CD20 single-chain variable fragments to enhance tumor recognition.

Non-covalent peptide conjugates enable efficient cytosolic delivery and mRNA knockdown, overcoming restricted diffusion across cell membranes.

Perillyl alcohol permeabilizes the blood brain barrier to transport therapeutic agents across the endothelial layer.

A GLP-1 derived pentapeptide composition curtails weight gain and insulin resistance through targeted molecular modification.

Segmented multi-chain CARs distribute binding and signaling domains across separate polypeptides to reduce background activation of immune cells.

Bispecific CAR T cells merge chlorotoxin and IL-13 domains to resolve single-antigen targeting limits in glioblastoma therapy.

Specific endonucleases inactivate inhibitory genes in NK cells, resolving limited cytotoxicity and durability constraints.

Omomyc inhibits Myc-dependent gene transactivation by forming heterodimers with wild-type Myc, resolving low specificity of small molecule inhibitors.

Engineered bacteria secrete therapeutic polypeptides using signal sequences and periplasmic chaperones to resolve low yields from misfolded proteins.

Bat-derived ASC2 antagonists target the adaptor protein to block inflammasome activation, resolving off-target toxicity from direct caspase inhibition.

Engineered T cells secrete minibodies locally at the tumor site to enhance killing while minimizing off-site toxicity.

Fusion proteins combine nuclear export and localization signals to transport therapeutic cargoes across multiple nuclei in multinucleate cells.

Engineered GAA fusion protein with a glycosylation-independent lysosomal targeting tag directs enzyme delivery to target tissues.

A regulatable chimeric antigen receptor uses a dimerization switch to couple signaling domains for controlled immune activation.

AT-CAR T cells use tagged antibodies as universal mediators to eradicate diverse tumors while minimizing off-tumor toxicity.

Apyrase-Annexin V fusion protein inhibits thrombosis by degrading ADP and binding phosphatidylserine.

Activating AMPK in immune cells shifts metabolism from glycolysis to oxidative phosphorylation, extending persistence for cancer immunotherapy.

PAR3 mimetic peptides target protease activated receptor 3 to treat chronic pain while reducing abuse potential and side effects.

Cell-based assays using surface-expressed anti-PEG antibodies quantify free PEG and PEGylated molecules at the nanogram level without radioactive waste.

Engineered dendritic cells with Flt3 signaling domains cross-present tumor antigens to overcome the limited efficacy of checkpoint inhibitors in solid tumors.

A segmented intrabody binds soluble mutant huntingtin and routes it to lysosomes, reducing aggregate formation while restoring cellular function.

Coupling CAR-T cells with unique B cell receptor ligands targets lymphoma malignancies through specific antigen recognition.

Nesting active agents within a protective LAP shell prevents premature interaction and reduces systemic toxicity.

IL-13Rα2 ligand directs therapeutic compounds to glioblastoma cells, overcoming poor targeting by localizing effectors to the cytosol or nucleus.

Cyclic peptide ligands inhibit indoleamine 2,3-dioxygenase 1 activity to overcome immune checkpoint inhibitor resistance in cancer therapy.

Engineered Staphylococcus aureus Cas9 systems and guide RNAs improve targeting precision while reducing off-target effects in eukaryotic genomes.

Optimized CDR sequences enhance binding affinity while humanized constant regions reduce immunogenicity and toxic side effects.